Increased expression of enolase  in human breast cancer confers tamoxifen resistance in human breast cancer cells

English | 正體中文 | 简体中文 | 全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2514661 線上人數 : 153

RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

Taipei Medical University Institutional Repository > 醫學科技學院 > 醫學檢驗暨生物技術學系所 > 期刊論文 > Item 987654321/3762

請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/3762

題名:	Increased expression of enolase  in human breast cancer confers tamoxifen resistance in human breast cancer cells
作者:	何元順 Shih-Hsin Tu;Chih-Chiang Chang;Ching-Shyang Chen;Ka-Wai Tam;Ying-Jan Wang;Chia-Hwa Lee;Hsiao-Wei LinTzu-Chun Cheng3;Ching-Shui Huang1;2;Jan-Show Chu6;Neng-Yao Shih7;Li-C
貢獻者:	醫學檢驗暨生物技術學系
關鍵詞:	Tamoxifen;Breast cancer;Enolase-1;Estrogen receptor alpha;Nuclear factor kappa B
日期:	2009
上傳時間:	2009-08-25 10:38:29 (UTC+8)
摘要:	Enolase-alpha (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90-fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, P = .017), poor nodal status (N > 3, P = .018), and a shorter disease-free interval (<==1 year, P < .009). We also found that higher-expressing ENO-1 tumors confer longer distance relapse (tumor/normal ratio = 82.8-92.4-fold) when compared to locoregional relapse (tumor/normal ratio = 43.4-fold) in postsurgical 4-hydroxy-tamoxifen (4-OHT)-treated ER+ patients (P = .014). These data imply that changes in tumor ENO-1 levels are related to clinical 4-OHT therapeutic outcome. In vitro studies demonstrated that decreasing ENO-1 expression using small interfering RNA (siRNA) significantly augmented 4-OHT (100 nM)-induced cytotoxicity in tamoxifen-resistant (Tam-R) breast cancer cells. These results suggest that downregulation of ENO-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy.
關聯:	Breast Cancer Research and Treatment.
資料類型:	article
顯示於類別:	[醫學檢驗暨生物技術學系所] 期刊論文

文件中的檔案:

檔案	大小	格式	瀏覽次數
73.pdf	955Kb	Adobe PDF	136	檢視/開啟
73.pdf	955Kb	Adobe PDF	95	檢視/開啟
全文.txt	0Kb	Text	203	檢視/開啟
摘要.pdf	35Kb	Adobe PDF	181	檢視/開啟

在TMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

著作權聲明 Copyright Notice

本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。
The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.
瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。
By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.
本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。
TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

資料載入中.....